Navigation Links
Study Revises Dynamin's Role in Nerve Cell Function

An unexpected finding on how nerve cells signal to one another could rewrite the textbooks on neuroscience, says a collaborative team of researchers at Weill Cornell Medical College and Yale University.

Their study, published as a high-profile research article in the journal Science, suggests that a key cellular enzyme called dynamin 1 is not essential to all synaptic transmission, as experts had previously assumed.

Dynamin has long been a focus of research for its role in packaging chemical signals, called neurotransmitters, into tiny synaptic vesicles within the cell.

The new study finds that the enzyme is not always necessary for this process. Instead, dynamin 1 goes into action only when the synapse enters moments of especially high activity.

'In that sense, dynamin 1 remains crucial, allowing the synapse the freedom to function under all conditions,' explains co-senior author Dr. Timothy Ryan, professor of biochemistry at Weill Cornell Medical College.

The discovery is a potentially important new piece of the puzzle for scientists investigating neurological injury and disease.

'In the long run, what we're trying to achieve here is a kind of biochemical repair manual' for the brain and brain cells,' Dr. Ryan explains. 'So, in the future, if we find out that a particular illness is caused by a flaw in dynamin 1 function or proteins that interact with dynamin 1, we'll have answers on hand to help fix that.'

Dynamin 1 is one of a family of enzymes involved in synaptic vesicle endocytosis a reverse of the process of transmission of cellular signaling chemicals, whereby molecular components of the vesicle are retrieved from the synapse surface and fit back into a new vesicle to be recycled for reuse after the vesicle has discharged its neurotransmitter. One of the steps in this recycling is a biochemical process called fission.

'Early work with the Drosop hila fruit fly established dynamin 1's role in this vesicle recycling process,' Dr. Ryan explains. 'Essentially, the enzyme undergoes a chemical change whereby it physically squeezes off a piece of the old vesicular membrane creating a brand new vesicle poised to take on a new load of neurotransmitter.'

Based on this work in fruit flies, neuroscientists had assumed that dynamin 1 was necessary for the growth and function of all synaptic transmission.

But Dr. Ryan, along with co-senior author Dr. Pietro De Camilli, a Howard Hughes Medical Institute investigator and professor of cell biology at Yale, decided to test that notion.

Dr. De Camilli's laboratory in New Haven had worked hard to develop a unique, genetically engineered mouse without dynamin 1. If the enzyme was essential to all synaptic activity, these mice would die very soon after birth.

But the pups were born, and initially appeared healthy. 'That was the really big surprise here,' Dr. Ryan says. 'Pups lacking dynamin 1 moved and suckled just like normal pups at birth.'

Lab study revealed that synaptic activity in these mice was functioning at a low level enough to keep the mice alive over the short term without dynamin 1.

'The enzyme's function appears to be much more subtle than we had imagined,' Dr. Ryan says. 'It may not be necessary under conditions of low synaptic activity. In those cases, we suspect that other related enzymes, such as dynamin 2 and 3, may shoulder the load and carry out some residual function.'

'But as soon as cells require higher levels of synaptic activity, dynamin 1 becomes absolutely necessary,' he says.

Normal growth and function demand that neurons work at high capacity, so young mice without dynamin 1 eventually did die off, usually within a week or two of birth.

'These findings really change our outlook on dynamin 1, and on synaptic vesicle endocy tosis in general,' Dr. Ryan says. 'It's an exciting new discovery, one that we didn't expect. But all good science is built on surprises.'

This work was funded by the G. Harold and Leila Y. Mathers Charitable Foundation, the U.S. National Institutes of Health, AIRC (Associazione Italiana per la Ricerca sul Cancro), AICR (American Institute for Cancer Research), Telethon (an Italian foundation), FIRB (Fondo per gli investimenti per la ricerca di base) and COFIN/PRIN, the Canadian Institutes of Health Research, the Human Frontiers Science Program, and the Federazione Italiana per la Ricerca sul Cancro.

Co-researchers include lead author Dr. Shawn M. Ferguson, Mitsuko Hiyashi, Chiara Collesi, Dr. Silvia Giovedi, Dr. Andrea Raimondi, Dr. Liang-Wei Gong, Dr. Richard Flavell and Summer Paradise all of the HHMI and Yale University; Dr. Markus Wolfel and Dr. Gero Miesenbock, of Yale University; Dr. Gabor Brasnjo, of Weill Cornell Medical College; and Dr. Pablo Ariel, of Weill Cornell Medical College and The Rockefeller University.


Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:

(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... of Australia,s successful biotechnology scientists, Dr ... company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is ... the ASX. Noxopharm is a clinic-ready company with its ... clinical study later this year. ... facing cancer patients - the ability of cancers to become resistant ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology: